Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases.
To contact Derek email him directly: derekb.lowe@gmail.com
Twitter: Dereklowe
I have Schedule D to wrestle with tonight, so it's time for some linking and blogroll additions. I'll start with a relatively new blog from a pharma consultant, Eye on FDA, and that'll do it from the industrial side this time.
The rest are from academia, some pure chemistry sites such as Dylan Stiles', which I've already linked to. I enjoy his site a lot, but one thing that it tells me is something that I already knew - namely, that I'm not 25 any more. Another blogging chem grad student is Paul Bracher, at Harvard. Another site for hard-core organic chemistry fans is Totally Synthetic. I did just this sort of thing for my PhD, and it's a lot more fun to read about than it is to do. Another blog from inside academia, this time from a post-doc, is Interfacial Science. Another post-doc can be found at Post Doc Ergo Propter Doc.
I can also recommend Nature's venture into chem-blogging, the group-written Sceptical Chymist. (That's the name I put on my first notebook in my first-year Quantitative Analysis course, actually - Robert Boyle is definitely worth remembering).
And finally, there's Peter Rost, famously ex-Pfizer. You're unlikely to find very many points of agreement between his worldview and mine, but you can see for yourself here.
Y'know, that's a blog post in itself. But the short version is no, over the last few years I've had the usual mix of winners and losers. And my biggest losers, almost without exception, have been my attempts to apply my knowledge of pharma and biotech to small companies with growth potential.
There are two ways to interpret these results. . .
1. shrinkette on April 10, 2006 9:15 PM writes...
Good luck with Schedule D. This year, for the first time in my life, I had to pay Alternative Minimum Tax. :^(
Permalink to Comment2. Derek Lowe on April 10, 2006 10:09 PM writes...
We missed the AMT by a hair this year - each year the damn thing gets closer, and I'm afraid that next year we may succumb.
My Schedule D is a bit lively, but it's nothing compared to the 2000 and 2001 returns, which were downright Proustian in length and complexity. . .
Permalink to Comment3. tom bartlett on April 11, 2006 8:40 AM writes...
So, how'd you do? Did your extensive knowledge of The Business lead you to profit or loss?
Permalink to Comment4. Derek Lowe on April 11, 2006 9:38 AM writes...
Y'know, that's a blog post in itself. But the short version is no, over the last few years I've had the usual mix of winners and losers. And my biggest losers, almost without exception, have been my attempts to apply my knowledge of pharma and biotech to small companies with growth potential.
There are two ways to interpret these results. . .
Permalink to Comment5. tom bartlett on April 11, 2006 9:59 AM writes...
"There are two ways to interpret these results. . ."
I understand. Heck, I hold some ELN.
Permalink to Comment6. Milo on April 11, 2006 12:23 PM writes...
So can we expect witty critiques of Rost's posts?
Permalink to Comment